scholarly journals 5q Minus Myelodysplasia Associated with Multiple Epithelioid Granulomas within Conventional Renal Cell Carcinoma

2012 ◽  
Vol 2012 ◽  
pp. 1-4
Author(s):  
Rahul G. Matnani ◽  
Roshan K. Patel ◽  
Stephen E. Strup ◽  
Rouzan G. Karabakhtsian

A 69-year-old Caucasian female, with a previous diagnosis of 5q minus myelodysplastic syndrome, presented with conventional renal cell carcinoma (RCC) associated with multiple-epithelioid nonnecrotizing granulomas. Two previous reports of sarcoidosis, primarily involving the lung and skin, have been described in patients with 5q minus myelodysplasia. A cluster of closely linked genes encoding for cytokines such as IL-4, IL-5, and IL-3 are present on chromosome 5q. Hence, in sarcoidosis, cytokine imbalances associated with the deletion of these cytokine genes have been postulated. However, an occurrence of epithelioid granulomas within a carcinoma, in preexisting clonal myelodysplastic syndrome, has not been described. The patient, in the current study, had long standing 5q minus deletion, clinically characterized by refractory anemia associated with hypolobated megakaryocytes. However, the patient's history was negative for sarcoidosis and the extensive nonnecrotizing epithelioid granulomas were confined within RCC. Due to the absence of Th-2 cytokines, such as IL-4 and IL-5, in a subset of 5q minus myelodysplastic syndrome, proinflammatory Th-1 cytokines such as IFN-γand TNF-αmay be exaggerated in an environment conducive to antigen expression. Hence, we propose a greater susceptibility for the development of granulomas, at least in a subset of patients with 5q minus myelodysplasia.

2006 ◽  
Vol 175 (4S) ◽  
pp. 241-242 ◽  
Author(s):  
Stephen Brassell ◽  
Ricardo F. Sanchez-Ortiz ◽  
Surena F. Matin ◽  
David A. Swanson ◽  
Christopher G. Wood

2021 ◽  
Vol 79 ◽  
pp. S752
Author(s):  
K. Mitsunari ◽  
Y. Miyata ◽  
T. Matsuo ◽  
K. Ohba ◽  
Y. Mukae ◽  
...  

2005 ◽  
Vol 20 (3) ◽  
pp. 450 ◽  
Author(s):  
Jeong Seok Hwa ◽  
Hyo Jin Park ◽  
Jae Hun Jung ◽  
Sung Chul Kam ◽  
Hyung Chul Park ◽  
...  

2019 ◽  
Vol 10 (21) ◽  
pp. 5124-5129 ◽  
Author(s):  
Donat Peter Sarlos ◽  
Maria V Yusenko ◽  
Lehel Peterfi ◽  
Arpad Szanto ◽  
Gyula Kovacs

2016 ◽  
Vol 10 (9-10) ◽  
pp. 306
Author(s):  
Gregory W. Hosier ◽  
Matthew T. Roberts

Vemurafenib is a selective inhibitor of overactive BRAF oncogene with a substitution of lysine for glutamic acid at residue 600 (BRAFV600E), a mutation expressed in approximately 50% of all melanomas. We report a case of a patient with metastatic melanoma treated with vemurafenib, who subsequently presented with a biopsy-proven conventional renal cell carcinoma (RCC). We observed an initial complete regression of the mass while on vemurafenib. This was unexpected, given that vemurafenib is a specific inhibitor of BRAFV600E and most RCCs do not harbour this mutation.


Sign in / Sign up

Export Citation Format

Share Document